CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Anakinradrug
Likely dose
Anakinra 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00332254
NCT00332254Phase 2Completed

IL-1ra for Prevention of Chondropathy Following Knee Injury

Duke University·interventional·Posted Jun 1, 2006·Updated May 30, 2013

In Brief

A Phase 2 clinical trial evaluating Anakinra for Knee Injury. Completed, enrolled 10 participants across 1 site.

Detailed Summary

Individuals who have had a severe knee injury have an increased risk of developing arthritis of the knee and at a much earlier age than would otherwise be expected. The swelling and inflammation that occur after injury are believed to be responsible for this cartilage damage. The cartilage (material that provides a cushion in the knee) is the primary protection from what is called degenerative arthritis or osteoarthritis. We hope to reduce this swelling and prevent the damage to cartilage that occurs after injury by injecting a medication that blocks one of the proteins responsible for inflammation and cartilage breakdown. This protein is called interleukin-1 and can be inhibited by an interleukin-1 receptor antagonist called anakinra. Anakinra will be injected directly into the injured knee and response to the injection will be measured by symptoms and analysis of cartilage breakdown in the knee fluid and blood.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKnee Injury
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 1, 2006
Enrollment StartMar 1, 2006
Primary CompletionJun 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 20.1 years ago

Interventions

Anakinradrug

150 mg IL1Ra ia x1 vs saline ia x1